Table 2 |
||||
|
Baseline levels of coagulation markers |
||||
|
Coagulation marker |
Group A |
Group B |
P value |
Normal range (reference value) |
|
|
||||
|
Prothrombin fragment F1+2 (nmol/l) |
2.5 (0.9–3.8) |
4.1 (2.3–6.6) |
0.20 |
0.3–1.6 |
|
Soluble tissue factor (pg/ml) |
126 (73–216) |
207 (30–322) |
0.59 |
55–256 |
|
Activated factor VII (mU/ml) |
61 (14–141) |
97 (20–267) |
0.52 |
16–142 |
|
Tissue factor pathway inhibitor (ng/ml) |
167 (104–192) |
127 (56–200) |
0.83 |
39–149 |
|
Antithrombin (%) |
78 (46–100) |
45 (16–81) |
0.09 |
80–140 |
|
Protein C (%) |
63 (29–164) |
41 (16–89) |
0.34 |
65–110 |
|
Plasmin–antiplasmin complexes (ng/ml) |
682 (635–788) |
727 (281–1287) |
1.0 |
221–512 |
|
Tissue-type plasminogen activator (ng/ml) |
14.3 (7.0–44.6) |
11.7 (8.6–51.7) |
0.75 |
1.5–15 |
|
Plasminogen activator inhibitor type 1 (ng/ml) |
135 (16–275) |
526 (129–2191) |
0.06 |
10–70 |
|
Kallikrein–C1-inhibitor complex (mU/ml) |
8.2 (5.1–9.9) |
11.1 (8.5–18.5) |
0.02 |
<0.6 |
|
Activated factor XII–C1-inhibitor complex (mU/ml) |
1.6 (1.3–1.8) |
2.4 (1.8–4.4) |
0.02 |
<0.5 |
|
Platelet count (× 109/l) |
136 (90–329) |
63 (30–101) |
0.02 |
150–350 |
|
Prothrombin time (s) |
13.5 (12.7–16.9) |
17.5 (15.2–26.1) |
0.05 |
10–13 |
|
Activated partial thromboplastin time (s) |
25 (21–29) |
37 (27–57) |
0.02 |
21–27 |
|
|
||||
|
Group A, patients with increased thrombin generation; group B, patients without increased thrombin generation. Data presented as median (range). |
||||
|
Bouman et al. Critical Care 2006 10:R150 doi:10.1186/cc5080 |
||||
